Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Metformin in Advanced Melanoma
NCT03311308Phase 1Active, not recruiting
- Start
- Feb 2018
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liquid metformin (Aspargo Labs) in melanoma (2 arms). Primary endpoint: Ki-67 proliferation index in T cell up to 4 years. Started Feb 2018; status: active, not recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03311308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311308.